The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice (Q38322718)

2 September 2017

The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice (English)

1 reference

2 September 2017

1 reference

1 reference

Chun Wang

1

1 reference

2 September 2017

Hong Li

2

1 reference

2 September 2017

Sheng-Guang Chen

3

1 reference

2 September 2017

Jin-Wei He

4

1 reference

2 September 2017

Chun-Jun Sheng

5

1 reference

2 September 2017

Xiao-Yun Cheng

6

1 reference

2 September 2017

Shen Qu

7

1 reference

2 September 2017

Ke-Sheng Wang

8

1 reference

2 September 2017

Mei-Ling Lu

9

1 reference

2 September 2017

Yong-Chun Yu

10

1 reference

2 September 2017

14 August 2012

1 reference

Journal of Bone and Mineral Metabolism

2 September 2017

1 reference

2 September 2017

30

1 reference

2 September 2017

6

1 reference

2 September 2017

630-637

1 reference

https://scigraph.springernature.com/pub.10.1007/s00774-012-0374-0

2 September 2017

0 references

cites work

Prevalence of diabetes among men and women in China

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Relationship between bone ingrowth, mineral apposition rate, and osteoblast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Metformin reverses the deleterious effects of high glucose on osteoblast function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Pioglitazone can downregulate bone morphogenetic protein-2 expression induced by high glucose in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00774-012-0374-0

Animal models in type 2 diabetes research: an overview.

21 January 2018

1 reference

12 December 2020

Bone health in diabetes: considerations for clinical management

1 reference

12 December 2020

The role of PPARγ for the osteoblastic differentiation.

1 reference

12 December 2020

Thiazolidinedione use and the risk of fractures.

1 reference

12 December 2020

Distal upper and lower limb fractures associated with thiazolidinedione use.

1 reference

12 December 2020

10.1007/S00774-012-0374-0

Identifiers

DOI

1 reference

2 September 2017

1 reference